Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

BACKGROUND: Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited. OBJECTIVES: We provide cumulative safety data from five prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Christine, Louie, Thomas, Bancke, Lindy, Guthmueller, Beth, Harvey, Adam, Feuerstadt, Paul, Khanna, Sahil, Orenstein, Robert, Dubberke, Erik R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272687/
https://www.ncbi.nlm.nih.gov/pubmed/37333464
http://dx.doi.org/10.1177/17562848231174277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272687/
https://www.ncbi.nlm.nih.gov/pubmed/37333464
http://dx.doi.org/10.1177/17562848231174277

Ejemplares similares